Aardvark Therapeutics is a biopharmaceutical company focused on small molecule therapies for the treatment of obesity and metabolic diseases. Aardvark’s lead product (BitteraTM) is a first-in-class oral drug that disrupts hunger signalling and regulates energy homeostasis
Location: United States, California, San Diego
Employees: 11-50
Total raised: $114M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Vickers Ve... | vickersven... |
| 28.11.2024 | LG Technol... | lgtechvent... |
| 20.06.2023 | Premier Pa... | premierpar... |
| 16.08.2024 | SymBiosis | symbiosis.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.05.2024 | Series C | $85M | - |
| 05.08.2021 | Series B | $29M | - |
Mentions in press and media 8
| Date | Title | Description |
| 15.07.2025 | OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company | BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their famili... |
| 22.06.2025 | A revolutionary drug for extreme hunger offers clues to obesity’s complexity | But what’s becoming clear is that obesity isn’t one disease — it’s many, said Jack Yanovski, a senior obesity researcher at the National Institutes of Health, who co-authored some of the Vykat XR studies. Researchers are learning that obesi... |
| 24.12.2024 | Tolerance Bio: $20.2 Million (Seed) Raised To Develop Approaches To Increase Healthspan | Tolerance Bio – a biopharmaceutical company pioneering approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance – announced the formation of its Scie... |
| 09.05.2024 | Aardvark Therapeutics Raises $85M in Series C Financing | Aardvark Therapeutics, Inc., a San Diego, CA-based clinical-stage biopharmaceutical company, raised $85m in Series C financing. The round was led by Decheng Capital, with participation from Cormorant Asset Management, Surveyor Capital, SymB... |
| 09.05.2024 | Aardvark Therapeutics Raises $85M | San Diego-based Aardvark Therapeutics announced today that it has raised $85M in a Series C funding round. The funding was led by Decheng Capital and also included Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial ... |
| 06.08.2021 | Aardvark Therapeutics Closes $29M Series B Funding | Aardvark Therapeutics, Inc., a San Diego, CA-based clinical stage biopharmaceutical company, completed a $29m Series B financing. The round was led by Sorrento Therapeutics with participation from existing investors including Vickers Ventur... |
| 05.08.2021 | Aardvark Therapeutics Gets $29M In Series B | San Diego-based Aardvark Therapeutics, a biopharmaceuticals company focused on metabolic diseases, said this morning that it has raised $29M in its Series B funding round. The funding was led by Sorrento Therapeutics, and also included Vick... |
| - | Aardvark Therapeutics | “Aardvark Therapeutics – Restoring Equilibrium Through Gut-Brain therapeutics” |